cagrilintide phase 1 Once-weekly for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding 2 trial Cagrilintide is an amylin analogue

BMI over 30, or over 27 with metabolic risk factors History of weight loss followed by regain Concerns about muscle loss during weight reduction Signs of age-related growth hormone decline Commitment to dietary and exercise optimization alongside peptide use Understanding of research compound status and associated considerations Those specifically concerned about muscle preservation during weight loss make particularly appropriate candidates for the combined protocol

Appetite Suppression: By slowing gastric emptying and reducing appetite, GLP-1 peptides make it easier to adhere to a calorie-controlled diet

3 vials: 9 mL 1 10 mL bottle 5 vials: 15 mL 2 10 mL bottles 6 vials: 18 mL 2 10 mL bottles Alcohol Swabs: One for the vial stopper + one for the injection site each day

Athletes requiring rapid recovery from serious injuries and post-operative patients needing accelerated healing timelines are also excellent candidates